Paratek Reports Results of Nuzyra (omadacycline) in P-III OASIS-2 Study for Skin Infections

 Paratek Reports Results of Nuzyra (omadacycline) in P-III OASIS-2 Study for Skin Infections

Paratek Reports Results of Nuzyra (omadacycline) in P-III OASIS-2 Study for Skin Infections

Shots:

  • The P-III OASIS-2 study involves assessing of Nuzyra (qd, PO) vs Linezolid (PO, bid) in 735 patients with acute bacterial skin and skin structure infections (ABSSSI)
  • The P-III OASIS study results: met its 1EPs i.e, ECR rate (87.5% vs 82.5%); Clinical success rates at PTE in the mITT & CE population (84.2% & 97.9% vs 80.8% & 95.5%); efficacy profile is consistent with OASIS-1 study results, published in The Lancet Infectious Diseases
  • Nuzyra is a novel antibiotic, comprising both IV & oral formulation, designed to overcome tetracycline resistance exhibiting broad-spectrum activity and has received FDA’s approval for CABP and ABSSSI in adults on Oct 02, 2019

Click here to­ read full press release/ article | Ref: Paratek | Image: The Pharma Letter

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post